ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Li, Shan; Wu, Junrong; Chen, Yongbin; Tang, Weizhong; Peng, Qiliu; Deng, Yan; Xie, Li; Wang, Jian; Huang, Shan; Li, Ruolin; Qin, Xue; Zhao, Jinmin.
; 25(1): 106-14, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24025563
Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
Metabonomic profiling of bladder cancer.
Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Overexpression of Karyopherin Subunit alpha 2 (KPNA2) Predicts Unfavorable Prognosis and Promotes Bladder Cancer Tumorigenicity via the P53 Pathway.
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
Lectins as possible tools for improved urinary bladder cancer management.
Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor.
Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts.
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.